Supriya Lifescience shares tumbled 11.75% to ₹925.2 during Monday's trading session, marking a dramatic reversal from the stock's previous surge. According to Business Standard, the pharmaceutical company was the biggest loser in the BSE's 'A' group on June 2, 2026. The stock had previously surged 15% to hit a new high of ₹968.70 on Friday following strong Q4FY26 earnings, but the recent decline shows significant volatility in the stock price. Trading volumes were elevated with 96,673 shares traded against the average daily volume of 38,616 shares over the past month, indicating heightened investor interest during the sell-off.
The pharmaceutical company delivered exceptional financial results for the January-March 2026 quarter. As reported by Business Standard, revenue grew 50.2% year-over-year to ₹276.53 crore compared to ₹184.11 crore in Q4FY25. EBITDA stood at ₹97.62 crore with a margin of 35.3%, while the profit after tax increased 47.4% YoY to ₹74.23 crore, compared to ₹50.37 crore in the previous year. The company operates as a cGMP-compliant business focused on active pharmaceutical ingredients (API) manufacturing across therapeutic segments including antihistamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic products. According to The Financial Express, the company's market capitalization stands at ₹7,796.37 crore as of May 29, 2026, with a P/E ratio of 37.28 and P/B ratio of 6.89.
According to Business Standard, the anesthetic segment continued to be the primary growth driver, contributing 54% of total revenues in FY26 compared to 49% in FY25. The vitamins segment also witnessed improved traction with its contribution increasing to 12% from 11% during the same period. Export contribution remained strong at approximately 82% of FY26 revenues, supported by diversified customer relationships and continued penetration into regulated markets. Capacity utilisation improved to 74% in FY26 from 70% in FY25, supported by the ramp-up of Module E at the Lote facility and continued operational efficiencies. As per The Financial Express, the company's total operating revenue stands at ₹827.88 crore for the year ended March 31, 2026, with equity capital of ₹16.10 crore.
Choice Institutional Equities maintains a 'BUY' rating on Supriya Lifescience with a target price of ₹1,030 per share, as reported by Business Standard. The brokerage firm believes the company's leadership in niche therapies and strong backward integration capabilities should support margin expansion from FY28E, despite planned near-term contraction. The analysts have marginaly revised FY27/28E estimates upwards by 4.9%/4.1% and continue to value the stock at 30x FY27–28E EPS. Key growth drivers identified include further expansion in Europe, launches in high-margin therapies across regions, and ramp-up of the CDMO segment. According to The Financial Express, the stock has dividend yield of 0.00 per annum, reflecting the company's focus on reinvesting profits for growth.
